---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253449353.md"
description: "ZHIFEI-BIOL: The company's application for clinical trials of the acellular DTP (component) combined vaccine (for adults and adolescents) has been accepted"
datetime: "2025-08-18T11:14:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253449353.md)
  - [en](https://longbridge.com/en/news/253449353.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253449353.md)
generator: "portal-rs"
---

# 

ZHIFEI-BIOL: The company's application for clinical trials of the acellular DTP (component) combined vaccine (for adults and adolescents) has been accepted

### Related Stocks

- [300122.CN](https://longbridge.com/en/quote/300122.CN.md)

## Related News & Research

- [The latest sign of influencer commerce heating up: Levanta just raised $22 million](https://longbridge.com/en/news/297162968.md)
- [Andritz wins repeat orders from Nanning Sun Paper for China pulp and paper project](https://longbridge.com/en/news/296993005.md)
- [PB Group auditor Prism Hong Kong rebrands as CLA Prism Hong Kong](https://longbridge.com/en/news/297161864.md)
- [My Mountain Mover Recognized Among the 2026 Inc. 5000 Fastest-Growing U.S. Companies](https://longbridge.com/en/news/297087696.md)
- [Trial for accused mastermind of 9/11 attacks set for June 2028](https://longbridge.com/en/news/297118954.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**